Ramelteon: A review of its use in insomnia

Drugs

Volumn 68, Issue 13, 2008, Pages 1901-1919

  Simpson, Dene ^a,b   Curran, Monique P ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Insomnia; Ramelteon, general

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CYTOCHROME P450 1A2; DEXTROMETHORPHAN; DONEPEZIL; ESCITALOPRAM; ESTAZOLAM; ESZOPICLONE; FLUCONAZOLE; FLUOXETINE; FLURAZEPAM; FLUVOXAMINE; HORMONE RECEPTOR STIMULATING AGENT; KETOCONAZOLE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MIDAZOLAM; OMEPRAZOLE; PLACEBO; PROLACTIN; QUAZEPAM; RAMELTEON; RIFAMPICIN; TEMAZEPAM; THEOPHYLLINE; TRIAZOLAM; UNINDEXED DRUG; VENLAFAXINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

AREA UNDER THE CURVE; BEDTIME DOSAGE; CIRCADIAN RHYTHM; CLINICAL TRIAL; COGNITION; COST CONTROL; DIZZINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; INSOMNIA; LIGHT DARK CYCLE; MONEY; MOTOR PERFORMANCE; NAUSEA; POLYSOMNOGRAPHY; PROLACTIN BLOOD LEVEL; REBOUND; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; SLEEP TIME; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CLINICAL TRIALS AS TOPIC; HALF-LIFE; HUMANS; INDENES; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 50249189246     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868130-00011     Document Type: Review

References (60)

1. Ancoli-Israel S. Sleep problems in older adults: putting myths to bed. Geriatrics 1997; 52 (1): 20-30
2. American Academy of Sleep Medicine. The International Classification of Sleep Disorders, revised. Diagnostic and coding manual. Rochester (MN): American Academy of Sleep Medicine, 2001
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association, 2000
4. World Health Organization. The ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization, 1992
5. National Institutes of Health. NIH State-of-the-science conference statement on manifestations and management of chronic insomnia in adults. NIH Consens Sci Statements 2005; 22 (2): 1-30
6. Roth T, Franklin M, Bramley TJ. The state of insomnia and emerging trends. Am J Managed Care 2007; 13 (5 Suppl.): S117-20
7. Doghramji J. The epidemiology and diagnosis of insomnia. Am J Manag Care 2006; 12 (8 Suppl.): S214-20
8. National Sleep Foundation. 2002 "Sleep in America" poll [online]. Available from URL: http://www.sleepfoundation.org/img/ 2002SleepInAmericaPoll.pdf [Accessed 2008 Apr 20]
9. Curry DT, Eisenstein RD, Walsh JK. Pharmacologic management of insomnia: past, present, and future. Psychiatr Clin North Am 2006 Dec; 29 (4): 871-93; abstract vii-viii
10. Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004; 5 (6): 523-32
11. 2 receptor agonist. Neuropharmacology 2005 Feb; 48 (2): 301-10
12. 3 as the quinone reductase 2. J Biol Chem 2000; 275 (40): 31311-7
13. Ebrahim I. Ramelteon: a new approach to managing insomnia. Future Neurology 2008; 3 (1): 9-18
14. Takeda Pharmaceuticals America Inc. Rozerem™ (ramelteon) tablets: prescribing information [online]. Available from URL: http://www.rozerem.com/ HCP/PI_1.aspx [Accessed 2008 Apr 7]
15. Yukuhiro N, Kimura H, Nishikawa H, et al. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res 2004 Nov 19; 1027: 59-66
16. Miyamoto M, Nishikawa H, Doken Y, et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004; 27 (7): 1319-25
17. Hirai K, Kita M, Ohta H, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005; 20 (1): 27-37
18. Richardson G, Zee P, Wang-Weigand S, et al. Circadian phase-shifting effects of daily ramelteon in healthy adults [abstract no. 196]. Society for Research on Biological Rhythms 10th Biennial Meeting program and abstracts; 2006 May 21-25; Sandestin (FL), 134
19. 2. J Clin Pharmacol 2007 Apr; 47 (4): 485-96
20. 2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006 Feb; 46 (2): 140-8
21. Hajak G, Ebrahim I, Hibberd M. Effect of ramelteon and zopiclone on body sway at peak plasma levels in chronic insomnia [abstract no. NR611]. Conference Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA), 261
22. Wang-Weigand S, Zammit G, Peng X. Placebo-controlled, double-blind trial examining the effects of ramelteon vs placebo with zolpidem as a reference on balance in older adults after middle-of-night awakening [abstract no. NR604]. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA), 258
23. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006 Oct; 63 (10): 1149-57
24. Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician 2007 Aug 15; 76 (4): 517-26
25. Bhat A, Shafi F, El Solh AA. Pharmacotherapy of insomnia. Expert Opin Pharmacother 2008; 9 (3): 351-62
26. Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006 Jan; 7 (1): 17-24
27. Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007 May; 23 (5): 1005-14
28. Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007 Aug 15; 3 (5): 495-504
29. 2 receptor agonist, in a first-night-effect model of transient insomnia [abstract no. 0701]. Sleep 2006; 29 (Suppl.): A238
30. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28 (3): 303-7
31. Wang-Weigand S, Mayer G, Roth-Schechter B. Long-term efficacy and safety of ramelteon 8 mg treatment in adults with chronic insomnia: results of a six-month, double-blind, placebo-controlled, polysomnography trial [abstract no. 525 plus poster]. 5th World Sleep Congress of the World Federation of Sleep Research and Sleep Medicine Societies; 2007 Sep 2-6; Cairns (QLD)
32. Kryger M, Roth T, Wang-Weigand S, et al. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath. Epub 2008 Jun 27
33. 2-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep Breath 2008; 12 (3): 243-50
34. Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther 2006 Oct; 28 (10): 1540-55
35. Pandi-Perumal SR, Srinivasan V, Poeggeler B, et al. Drug insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol 2007 Apr; 3 (4): 221-8
36. Karim A, Tolbert D, Cao C. Effects of fluoxetine on the systemic exposure of ramelteon (TAK-375) [abstract no. NR844]. Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY), 317
37. Karim Z, Bradford D, Siebert F, et al. Open-label assessment of the pharmacokinetics of ramelteon and donepezil coadministration in healthy adults [abstract no. NR606]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA), 259
38. Karim A, Bradford D, Siebert F, et al. Effect of multiple oral doses of escitalopram on the systemic availability of ramelteon, an MT1 and MT2 receptor agonist, in healthy adults [abstract no. 0700]. Sleep 2006 May 20; 29 Suppl.: A237-8
39. Karim A, Bradford D, Zhao Z. Effect of multiple oral doses of venlafaxine on the systemic availability of ramelteon, an MT1/MT2 receptor agonist [abstract no. P01.139]. Int J Neuropsy-chopharmacol 2006 Jul 1; 9 Suppl. 1: S138
40. Karim A, Moore R, Zhao Z, et al. Open-label assessment of the pharmacokinetics of ramelteon 8 mg and zolpidem 10 mg coadministration in healthy adults [abstract no. 45-P]. 36th Annual Meeting of the American College of Clinical Pharmacology; 2007 Sep 9-11; San Francisco (CA)
41. Karim A, Tolbert D, Cao C, et al. Study to assess the steady-state drug-drug interaction of omeprazole with ramelteon in healthy adults [abstract no. 0137]. Sleep 2005; 28 Suppl.: A46
42. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006 Jun; 7 (4): 312-8
43. FDA. Medical review document for application for approval of ramelteon [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2005/ 021782s000_Rozerem_medr.pdf [Accessed 2008 May 26]
44. Mini LJ, Wang-Weigand S, Zhang J. Sleep-promoting effects of ramelteon: a subanalysis of adults with severe sleep-initiation difficulty [abstract no. NR610]. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA), 261
45. Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007 Sep; 5 (3): 177-84
46. Jhaveri M, Seal B, Pollack M, et al. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States. Curr Med Res Opin 2007 Jun; 23 (6): 1431-43
47. Richardson G, Wang-Weigand S, Zhang J, et al. Long-term safety of ramelteon treatment in adults with chronic insomnia: a 1-year study [abstract no. 0685]. Sleep 2006; 29 Suppl.: A233
48. Richardson GS, Wang-Weigand S, Sainati S, et al. Long-term effects of ramelteon on endocrine function in patients with chronic insomnia in a double-blind, placebo-controlled phase III study [abstract no. P111-38]. Clin Pharmacol Ther 2006 Feb 1; 79 (2): 68
49. Nichols J, Alper C, Milkin T. Strategies for the management of insomnia: an update on pharmacologic therapies. Formulary 2007; 42 (2): 86-98
50. Silber MH. Clinical practice: chronic insomnia. N Engl J Med 2005 Aug 25; 353 (8): 803-10
51. Taylor JR, Vazquez CM, Campbell KM. Pharmacologic management of chronic insomnia. South Med J 2006; 99 (12): 1373-7
52. Pfizer. Halcion - triazolam tablets, USP CIV [online]. Available from URL: http://www.pfizer.com/files/products/uspi_halcion. pdf [Accessed 2008 May 1]
53. Mallinckrodt Inc. Restoril® - temazepam capsules USP; prescribing information [online]. Available from URL: http://www.restoril.com/pdf/ restoril_prod_pi.pdf [Accessed 2008 May 1]
54. Estazolam tablets: prescribing information [online]. Available from URL: http://www.drugs.com/ppa/estazolam.html [Accessed 2008 May 1]
55. Dolder C, Nelson M, McKinsey J. Use of non-benzodiazepine hypnotics in the elderly: are all agents the same? CNS Drugs 2007; 21 (5): 389-405
56. Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006; 332 (7538): 385-93
57. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep; a meta-analysis. Sleep Med Rev 2005; 9 (1): 41-50
58. 2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J 2004; 18 (14): 1646-56
59. Pandi-Perumal SR, Srinivasan V, Spence DW, et al. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 2007; 21 (12): 995-1018
60. National Institutes of Health. Safety of ramelteon in elderly subjects [online]. Available from URL: http://clinicaltrials.gov [Accessed 2008 Apr 17]